US Patent

US12247034 — Crystalline form of deuruxolitinib phosphate

Composition of Matter · Assigned to Sun Pharmaceutical Industries Inc · Expires 2044-05-10 · 18y remaining

Vulnerability score 17/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects a crystalline form of the drug substance deuruxolitinib phosphate, specifically polymorph Form 1.

USPTO Abstract

The present disclosure is directed to polymorph Form 1 of 1H-pyrazole-1-propanenitrile, β-(cyclopentyl-2,2,3,3,4,4,5,5-d 8 )-4-(7H-pyrrolo[2,3- d ]pyrimidin-4- yl )-, (βR)-, phosphate (1:1) (deuruxolitinib phosphate). Also disclosed are methods of treatment using polymorph Form 1 of deuruxolitinib phosphate and methods of making polymorph Form 1 of deuruxolitinib phosphate.

Drugs covered by this patent

Patent Metadata

Patent number
US12247034
Jurisdiction
US
Classification
Composition of Matter
Expires
2044-05-10
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Sun Pharmaceutical Industries Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.